ASN Kidney Week 2026:三款IgA肾病治疗药物最新临床数据摘要
Clinical trials generate promising results for improving kidney health
在2026年ASN Kidney Week期间,多篇IgA肾病III期临床试验结果显示,Atacicept在ORIGIN 3试验中显著降低尿蛋白/肌酐比值并获FDA加速批准;Sibeprenlimab在VISIONARY试验中将严重肾功能下降或肾衰竭风险较安慰剂降低97%;Telitacicept在TELIgan试验中减缓高风险患者的肾功能流失。
汇总三款针对IgA肾病III期药物的最新数据,呈现不同作用机制在延缓肾功能下降方面的具体结果。
The results of numerous high-impact Phase III clinical trials that could affect kidney-related medical care were presented in person at American Society of Nephrology Kidney Week 2026, Oct. 22–25.
Atacicept inhibits the cytokines B-cell activating factor (BAFF, also known as B-lymphocyte stimulator, or BLyS) and a proliferation-inducing ligand (APRIL) involved in the pathogenesis of IgA nephropathy. In the interim analysis of the Phase III ORIGIN 3 trial, atacicept achieved a statistically significant reduction in urinary protein-to-creatinine ratio at week 36.
Following FDA review, atacicept received accelerated approval. In the latest analysis of ORIGIN 3 through two years, atacicept demonstrated additional benefits for patients.
"ORIGIN 3 stands as a landmark trial in kidney medicine, demonstrating kidney protection with atacicept through stabilization of eGFR and a marked reduction in the risk of kidney disease progression. The safety profile was comparable to placebo, with no evidence of increased infection risk," said corresponding author Jonathan Barratt, MBChB, Ph.D., FRCP, of the University of Leicester.
"Together with a small-volume, self-administered autoinjector, these findings represent an important advance for patients with IgA nephropathy."
Sibeprenlimab targets the cytokine a proliferation-inducing ligand (APRIL), one of the immune-related drivers of IgA nephropathy, a condition that affects patients often at a young age and places them at a significant lifetime risk of kidney failure. In the Phase III VISIONARY trial, sibeprenlimab reduced the risk of serious kidney function loss or kidney failure in adults with IgA nephropathy by 97% compared with placebo, with kidney function remaining stable over two years.
"By selectively inhibiting APRIL, a fundamental driver of the disease, we are targeting the source of kidney damage and advancing what may be a new standard for treating IgA nephropathy," said corresponding author Dana Rizk, M.D., of the University of Alabama at Birmingham.
Dual inhibition of the cytokines B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) targets the underlying pathogenesis of IgA nephropathy.
In a report on the two-year efficacy and safety of the dual BLyS/APRIL inhibitor telitacicept in the Phase III TELIGAN trial, investigators showed that telitacicept slows kidney function loss and substantially reduces the risk of kidney failure in high-risk IgA nephropathy, with a favorable safety profile.
"These two-year findings confirm durable kidney protection for patients with high-risk IgA nephropathy," said corresponding author Jicheng Lv, M.D., Ph.D., of Peking University First Hospital.
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Clinical trials generate promising results for improving kidney health (2026, October 22) retrieved 22 October 2026 from https://medicalxpress.com/news/2026-10-clinical-trials-generate-results-kidney.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com